|
Market Research Report
Chugai: Pipeline * Products * Performance * Potential
|
Chugai:
Pipeline * Products * Performance * Potential published by Espicom Business Intelligence in October, 2009. This report consists of Pages: 80 and the price starts from US $ 1040.
Abstract
As a member of the Roche Group, Chugai has rights to develop and market all
pharmaceutical products which the Roche Group decides to commercialise in
Japan. This report provides a full review of the company's activities together
with sales forecasts for key products to 2010.
Chugai Pharmaceutical's net sales for 2005 were ¥327,200 million, an 11%
increase over 2004. Operating income was up by 54% to ¥79,200 million, due to
product sales increases and cost saving measures. Net income rose by 57% to
¥53,600 million, due mostly to extraordinary gains from milestone income from
Roche related to co-development of Actemra.
Chugai's reliance on the tough Japanese market has led to a range of
initiatives for overseas expansion. It is building an independent development
and sales infrastructure in Europe and other overseas markets and formulating
a marketing strategy that will establish an autonomous marketing network in
the US.
R&D Pipeline Overview
- Antevas has been filed for the treatment of disorders caused by
acute cerebrovascular diseases.
- ED-71 is an oral vitamin D3 derivative in Phase III trials for the
treatment of osteoporosis.
- VAL has completed Phase II trials in Japan for use in
post-hepatectomy/liver transplantation.
- CHS13340, a nasal spray formulation of recombinant human
parathyroid hormone, has been licensed from Daiichi Suntory Pharma, and is in
Phase II trials for osteoporosis.
- Tarceva is expected to be filed for non-small cell lung cancer in
the first half of 2006.
Major Products Forecast to 2010
- Rythmodan (Cardiovascular)
- Alfurol (Bone Metabolism)
- Epogin (Haematological)
- Neutrogin/Granocyte (Haematological)
- Sigmart/Ikorel (Cardiovascular)
- Rituxan (Anticancer)
- Tamiflu (Antiviral)
Table of Contents
Latest Results
EXECUTIVE SUMMARY
- Introduction
- Financial Performance 2005
- Sales and Marketing Position
- Income
- Sales, Costs and Operating Income
- Expenditure
- Capital Expenditure
- R&D Expenditure
- Divisional Performance
- Geographic Performance
- Sales by Geographic Area
- Sales by Geographic Area, 2005
- Company Strategy
- Merger with Nippon Roche
- Sunrise 2010
- Mergers, Acquisitions and Divestitures
- Key Agreements
- Production
- Employees
- Product/R&D Overview
- Key Products
- Recent Product Launches
- Recent Product Approvals
- R&D Strategy
- Sales Forecast
- Sales of Major Products (2000A-2010E)
- R&D Pipeline Overview
- Discontinued R&D Projects
- Conclusions
PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT
- Major Products, Therapeutic Areas and Sales
- Breakdown of Sales by Therapeutic Area, 2005
- Top Selling Products, 2006
- R&D Pipeline - Japan
- R&D Pipeline - Overseas
- Haematological - Products
- Major Launched Products
- Epogin
- Sales
- Indications
- Further Development
- Patents
- Competitor Products
- Sales Forecast
- Epogin Sales (2000A-2010E)
- Neutrogin/Granocyte
- Sales
- Key Markets/Indications
- Sales Forecast
- Neutrogin Sales (2000A-2010E)
- Haematology - R&D
- R&D Pipeline - Japan
- R744
- Haematology - Summary
- Growth Potential
- Limiting Factors
- Anticancer, Chemotherapeutic - Products
- Major Launched Products
- Femara
- Furtulon
- Herceptin
- Sales
- Key Markets/Indications
- Further Development
- Rituxan
- Sales
- Indications
- Safety Issues
- Sales Forecast
- Rituxan Sales (2000A-2010E)
- Tamiflu
- Sales
- Indications
- Competitor Products
- Sales Forecast
- Tamiflu Sales (2000A-2010E)
- Xeloda
- Sales
- Indications
- Further Development
- Anticancer, Chemotherapeutic - R&D
- R&D Pipeline - Japan
- Avastin
- Omnitarg
- Tarceva
- Anticancer, Chemotherapeutic - Summary
- Growth Potential
- Limiting Factors
- Cardiovascular, Respiratory - Products
- Major Launched Products
- Inhibace
- Renagel
- Sales
- Markets/Indications
- Rythmodan
- Rythmodan Sales (2000A-2010E)
- Sigmart/Ikorel
- Sales
- Licensees
- Indications
- Sales Forecast
- Sigmart Sales (2000A-2010E)
- Cardiovascular, Respiratory - R&D
- R&D Pipeline - Japan
- Antevas (AVS)
- Cardiovascular, Respiratory - Summary
- Hormones, Vitamins, Tonic - Products
- Major Launched Products
- Alfarol
- Alfarol Sales (2000A-2010E)
- Oxarol/OCT
- Sales
- Further Development
- Hormones, Vitamins, Tonic - Summary
- Metabolic - R&D
- Japanese R&D Pipeline
- CHS13340
- ED-71
- Ibandronic Acid (R484)
- R483
- Metabolic - Summary
- Gastrointestinal - Products
- Major Launched Products
- Kytril
- Ulcerlmin
- Gastrointestinal - R&D
- R&D Pipeline - Japan
- R&D Pipeline - Overseas
- Mitemcinal Fumarate (GM-611)
- VAL
- Gastrointestinal - Summary
- Central Nervous System - Products
- Central Nervous System - Summary
- Antibiotic - Products
- Major Launched Products
- Rocephin
- Other - Products
- Major Launched Products
- Actemra 200
- Key Markets/Indications
- Further Development
- Clinical Trial Results
- Pegasys
- Sales
- Indications
- Further Development
- Other - R&D
- R&D Pipeline - Japan
- R&D Pipeline - Overseas
APPENDIX 1- FINANCIAL PERFORMANCE
- Full Year Results 2005
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
APPENDIX 3 - KEY AGREEMENTS
- Abgenix Inc
- Cerus Corporation
- Cambrex Bio Science Walkersville
- Eli Lilly
- Genzyme General
- Roche
- 5th April 2002
- 3rd October 2002
- 25th February 2003
- 15th December 2003
- 27th April 2004
- Xencor Inc
APPENDIX 4 - INFRASTRUCTURE
- Research and Development Facilities
- Manufacturing Facilities
APPENDIX 5 - KEY PHARMACEUTICAL
- SUBSIDIARIES/JOINT VENTURES
- Subsidiaries
- Joint Ventures
APPENDIX 6 - PRODUCT INDEX
|
